FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI - Top-Institutions - MDSpire

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.

  • By

  • Kathryn Wighton

  • June 15, 2026

  • 3 min

Share

Top Institutions in Radiology

Brief introduction explaining scope and methodology.

  • #1

    HALO Diagnostics Desert Cities
    HALO Diagnostics Desert Cities

    Desert Hot Springs, CA

    Key Differentiators

    • Radiology

  • #2

    Maria Sklodowska-Curie National Research Institute of Oncology
    Maria Sklodowska-Curie National Research Institute of Oncology

    Warsaw, Poland

    Key Differentiators

    • Oncology
    • Radiology

  • #3

    University of Chicago Medical Center
    University of Chicago Medical Center

    Chicago, IL

    Key Differentiators

    • Radiology

  • #4

    European Society for Magnetic Resonance in Medicine and Biology
    European Society for Magnetic Resonance in Medicine and Biology

    N/A, N/A

    Key Differentiators

    • Radiology

  • #5

    European Society of Urogenital Radiology
    European Society of Urogenital Radiology

    N/A, N/A

    Key Differentiators

    • Urogenital Radiology

Original Source(s)

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

  • by Kathryn Wighton

  • June 15, 2026

Related Content

Shorter DAPT Tested Following CABG

TOP-CABG compared 3 months vs 12 months of ticagrelor plus aspirin following bypass surgery.

Medical Oddities: The Economics of Shut-Eye

Sleep became a commodity, tea became a therapy, and cats got a reprieve this week.

Automated deep learning–radiomics pipeline for non-calcified coronary plaque detection using non-contrast calcium score CT